- EMPIRE HOUSE, 3RD FLOOR, 214, DR. D. N. ROAD, FORT, MUMBAI 400 001 TEL: 91-22-22078381, 22078382 FAX: 91-22-22074294

 - CIN No.: L99999MH1942PLC003556 PAN No.: AAACC2056K

www.thechemopharmalaboratoriesltd.com EMAIL: chemopharmalab@gmail.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH JUNE, 2015

(Rs in '000)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30th June 2015 Unaudited	31st March 2015 Audited	30th June 2014 Unaudited	31st March, 2015
					Audited
1	Income from Operations				
	(a) Net Sales/ Income from Operations (Net of excise duty)		-		
	(b) Other Operating Income	785	2,480	1,102	5,044
	Total Income from operations (net)	785	2,480	1,102	5,044
2	Expenses				
	(a) Cost of materials consumed	-	-	-	-
	(b) Purchases of Stock-in-trade	-	-		-
	(c) Change in inventories of finished goods, work-in-progress and stock-in-trade			-	-
	(d) Employee benefits expenses	111	113	48	305
	(e) Depreciation and amortisation expense		(27)	9	
	(f) Other expenses (Any item exceeding 10% of the	14	34	42	242
	total expenses relating to continuing operations to be shown seperately)	14	34	72	242
	i) Professional Charges	9	341	-	448
	ii) Share Registry Expenses	19	21	18	85
	iii) Annual Listing Fees	225	-	1	125
	Total Expenses	378	482	116	1,205
3	Profit / Loss from Operation before other Income, Finance cost and exceptional items (1-2)	407	1,998	986	3,839
4	Other Income	-	-	-	
5	Profit / Loss from ordinary activities before Finance cost and exceptional items (3+4)	407	1,998	986	3,839
6	Finance Costs	-	-		170
7	Profit / Loss from ordinary activities after Finance cost but before exceptional items (5+6)	407	1,998	986	3,839
8	Exceptional Items	-	-	-	-
9	Net Profit/(Loss) from ordinary activities before tax (7+8)	407	1,998	986	3,839
10	Tax expenses	-	1,040	-	1,040
11	Net Profit/(Loss) from ordinary activities after 'ax (9+10)	407	958	986	2,799
12	Extra ordinary items (net of tax expenses Rs.	-	-	-	-
13	Net Profit/ (Loss) for the period (11+12)	407	958	986	2,799
14	Share of Profit/ (Loss) of associate*		-		
15	Minority interest *	-	-		-
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+14+15)*	407	958	986	2,799
17	Paid-up equity share Capital (face value of Rs. 10/- each)	15,000	15,000	15,000	15,000
18	Reserves excluding revaluation reserve as per balance sheet of previous accounting year	36,217	36,217	33,506	36,217
19	 i) Earning per share (before extraordinary items) of Rs. 10/- each) (not annualised): 				
	(a) Basic	0.27	0.64	0.66	1.87
	(b) Diluted				
19	Earning per share (after extraordinary items) of Rs. 10/- each) (not annualised):				
	(a) Basic	0.27	0.64	0.66	1.87
	(b) Diluted				



CHEMO PHARMA LABORATORIES LIMITED

EMPIRE HOUSE, 3RD FLOOR, 214, DR. D. N. ROAD, FORT, MUMBAI – 400 001

TEL: 91-22-22078381, 22078382 • FAX: 91-22-22074294

CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

www.thechemopharmalaboratoriesltd.com EMAIL: chemopharmalab@gmail.com

A	PARTICULARS OF SHAREHOLDING				
1	Public Shareholding				
	- Number of shares	1,081,719	1,081,719	1,081,719	1,081,719
	- Percentage of shareholding	72.12	72.12	72.12	72.12
19	Promoters and Promoter Group shareholding**				
	a) Pledged/Encumbered				
	- Number of shares	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total share capital of	NIL	NIL	NIL	NIL
	b) Non-Encumbered				
	- Number of shares	418,281	418,281	418,281	418,281
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100	100	100	100
	- Percentage of shares (as a % of the total share capital of company)	27.88	27.88	27.88	27.88

	Particulars	Quarter Ended 30.06.2015
В	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	NIL
	Received during the quarter	NIL
	Disposed of during the quarter	NIL
	Remaining unresolved at the end of the quarter	NIL

Note:

- 1. The above Unaudited Financial Results for the quarter ended 30.06.2015 have been reviewed by the Audit Committee in their Meeting held on 23.07.2015 and approved by the Board of Directors of its Meeting held on 23.07.2015. The Limited Review Report of Auditors M/s Batliboi & Purohit was also taken on record by the Board in its Meeting.
- 2. Separate segment reporting is not applicable to the company.

Place: Mumbai

Date : 23rd July 2015

For Chemo - Pharma Laboratories Limited

Director